EMA Reveals Initiative on New Biosimilars
The European Medicines Agency will launch a pilot project in February 2017 to test the added value and feasibility of tailored scientific advice for the development of biosimilar medicines.
The European Medicines Agency (EMA) will launch a pilot project in February 2017 to test the added value and feasibility of tailored scientific advice for the development of biosimilar medicines.
The EMA aims to provide developers of biosimilars with advice on the studies/tests they should be conducting, on the basis of the quality, analytical, and functional data they have already available for the product. This is designed to boost support the stepwise development of biosimilars that is recommended in European Union (EU) guidelines.
Biosimilars are biological medicines developed to be highly similar to another biological medicine (also known as the reference medicine) already authorized in the EU, according to an EMA statement. To obtain a marketing authorization, developers must establish similarity to the reference medicinal product in terms of quality characteristics, biological activity, safety and efficacy.
The pilot is open to all companies seeking scientific advice for the development of a biosimilar medicine. Any type of biosimilar will be accepted in the pilot, noted the EMA. Companies wishing to take part in the pilot will have a pre-submission meeting during which the suitability of the data package is reviewed. The EMA’s Scientific Advice Working Party will need an extra month in addition to normal scientific advice timelines to review the requests accepted in the pilot.
The pilot is planned to run until six scientific advice requests have been completed, with maximum one scientific advice request accepted per month, the statement concluded.
For the original release click here
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
